<DOC>
	<DOCNO>NCT00486694</DOCNO>
	<brief_summary>The purpose study determine whether propose first line treatment falciparum malaria region ( sulfadoxine-pyrimethamine + artesunate ) would worse treatment vivax malaria standard vivax treatment chloroquine . In area vivax falciparum malaria co-exist misdiagnosis vivax malaria falciparum unlikely ; important know whether adequate treatment receive case .</brief_summary>
	<brief_title>Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine Vivax Malaria</brief_title>
	<detailed_description>In area co-endemic falciparum vivax malaria incorrect differential diagnosis always risk . Where recommended treatment two diseases present problem effective treatment clinical cure either specie . Chloroquine remain effective treatment choice vivax malaria setting , spread chloroquine-resistant falciparum malaria across Asia , many country use artemisinin-based combination therapy species malaria . Differential diagnostic practice , improve parallel . In Afghanistan adoption sulfadoxine-pyrimethamine plus artesunate ( SP+AS ) first-line falciparum treatment raise prospect significant proportion vivax malaria misdiagnosed treated combination . SP consider limited efficacy vivax malaria efficacy SP+AS vivax establish area make switch . A randomized , non-inferiority trial compare SP+AS ( 1 day SP , 3 day AS ) chloroquine monotherapy undertaken 190 vivax patient Eastern Afghanistan . A margin equivalence 14 % , 90 % power 95 % CI ( two-sided α = 0.05 ) use . Standard WHO procedures vivo evaluation antimalarial drug follow . 180 individual complete trial day 42 . The primary outcome proportion patient free failure day 28 . Using per protocol analysis regimen result ≥96 % treatment success 28 day , significantly case fail CQ arm ( 46 % ) SP+AS arm ( 24 % ) day 42 . Based predetermined statistical criterion SP+AS show non-inferior standard chloroquine treatment . In area vivax infection might misdiagnosed falciparum infection treat SP+AS , patient management would good good standard CQ treatment .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<criteria>microscopy confirm P. vivax monoinfection age &gt; 2 year weight &gt; 5kg &gt; 1 asexual parasite per 10 field pregnant evidence concomitant infection serious disease recent use antimalarial drug severe malaria know allergy study drug</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Malaria , vivax</keyword>
	<keyword>Afghanistan</keyword>
	<keyword>Sulfadoxine-pyrimethamine</keyword>
	<keyword>drug resistance</keyword>
</DOC>